Opportunity Overview:

We are searching for a Gastroenterology Oncologist to join our department in New Orleans. We are an emerging NCI-designated comprehensive cancer center whose purposes are the treatment and control of cancer, the advancement of biomedical knowledge through laboratory and clinical research, and the training of physicians, scientists, and other healthcare workers. Our institution is among an elite group of 71 research universities, and we empower our physicians to become leaders in their field by collaborating with bench researchers, heading clinical trials, and publishing as primary authors for translational clinical trial research.

About the Role:

• You will be responsible for teaching fellows, residents, and medical students in addition to leading clinical trial research.
• 50% protected time (minimum), allowing for dedicated focus on academic pursuits.
• You will collaborate with a dedicated team of 3 Hepatologists and specialized Gastroenterology faculty.
• Receive strong APP support for clinical care.

Research Opportunities and Clinical Trials:

We have a variety of clinical trials that directly contribute to advancing treatment options for this specific cancer population. You will be at the forefront of new immunotherapy and chemotherapy regimens while collaborating with a team focused on improving patient outcomes and pioneering leading-edge research.

Trial 1: MSI-H/dMMR Gastric or GEJ Cancer

• This trial is for patients with a specific genetic mutation (MSI-H/dMMR) in gastric or gastroesophageal junction cancer.
• It investigates a new immunotherapy drug, atezolizumab, for controlling the spread of cancer.
• The trial will compare atezolizumab alone (monotherapy) and combined with chemotherapy.

Trial 2: Inoperable Colorectal Liver Metastases

• This trial is for patients with inoperable cancer that has spread to the liver from the colon or rectum.
• It compares a new approach using Hepatic Arterial Infusion (HAI) pump chemotherapy alongside the standard treatment to the standard treatment alone.
• HAI delivers high doses of chemotherapy directly to the liver tumors, potentially improving tumor control and survival.

Trial 3: Resected Pancreatic Cancer with BRCA Mutation

• This Phase II clinical trial studies the effectiveness of adding olaparib, a drug that blocks DNA repair, to the treatment plan of patients with pancreatic cancer.
• The patients must have undergone surgery to remove the cancer (resection).
• They must also have a specific genetic mutation (BRCA1, BRCA2, or PALB2).
• The goal is to see if blocking DNA repair in cancer cells with these mutations helps kill them.

Location:

• This historic city also offers state-of-the-art medical facilities, professional sports teams, and excellent major university programs.

JN -[Register to View] 4